Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

Launched by M.D. ANDERSON CANCER CENTER · Oct 14, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how patients who are at high risk for opioid overdose and their caregivers feel about using a nasal spray called naloxone. Naloxone can quickly reverse the effects of an opioid overdose and is often prescribed alongside opioid medications. The study aims to understand the beliefs and attitudes of these patients and caregivers, which can help improve how naloxone is prescribed and how education about it is provided.

To participate in this trial, patients need to have received a prescription for intranasal naloxone in the past year and should not have any serious cognitive issues. Caregivers, who can be family members or friends, must also be able to understand and communicate in English. They can give their consent either in person or over the phone. This trial is currently recruiting participants, and it offers a chance to share important insights that could help better support those at risk of opioid overdose.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients must have been prescribed intranasal naloxone in the past 1 year
• • Patients and caregivers must be able to understand, read, write, and speak English
• • Patients must have no clinical evidence of cognitive impairment, as determined by the palliative care provider (Memorial Delirium Assessment Scale score of \>= 7)
• • Patients must sign an informed consent
• • Caregivers may sign an informed consent if available during the visit
• • Caregivers may verbally consent over the phone if not present during the visit
• • Caregiver must be a friend, significant other or family member
• • Caregivers must have no evidence of cognitive impairment, as determined based on orientation questions pertaining to the date, day of the week, time, and place
• Exclusion Criteria:
• • PATIENT: Emotional or psychosocial distress as identified by the patient's palliative care
• • PATIENT: Participants with Edmonton Symptom Assessment System (ESAS) anxiety score of \> 6